-

ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference as follows:

Date:

 

Monday, September 12, 2022

Time:

 

12:30PM ET

Webcast:

 

Click Here

The webcast will be accessible via the Company’s website at www.anipharmaceuticals.com, in the Investors section under Events and Presentations.

ANI will be participating in 1x1 meetings on September 12. Meetings can be requested via H.C. Wainwright.

About ANI

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.

Contacts

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Media:
Faith Pomeroy-Ward, ANI Pharmaceuticals, Inc.
T: 817-807-8044
E: Faith.pomeroyward@anipharmaceuticals.com

Industry:

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP
Release Versions
English

Contacts

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Media:
Faith Pomeroy-Ward, ANI Pharmaceuticals, Inc.
T: 817-807-8044
E: Faith.pomeroyward@anipharmaceuticals.com

More News From ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Jefferies Healthcare Conference in New York City as follows: Date:         Friday, June 9, 2023             Time:         8:30 a.m. ET             Webcast:         Click here The live and archived webcast of the presentation will be accessible from the Company’s website at www...

ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) today announced the closing of its previously announced underwritten public offering. A total of 2,183,545 shares of its common stock were sold at a public offering price of $39.50 per share, inclusive of the exercise in full of the underwriters’ option to purchase an additional 284,810 shares of common stock. The gross proceeds of the offering to the Company are approximately $86.25 million, bef...

ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Applications (ANDAs) for Methsuximide Capsules USP, 300 mg and Alendronate Sodium Oral Solution 70 mg (base)/75 mL. Methsuximide Capsules has been granted 180-day Competitive Generic Therapy (CGT) Exclusivity, and Alendronate Sodium Oral Solution is eligible for CGT Exclusivity upon launch....
Back to Newsroom